BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9489630)

  • 1. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.
    Schiller G; Vescio R; Freytes C; Spitzer G; Lee M; Wu CH; Cao J; Lee JC; Lichtenstein A; Lill M; Berenson R; Berenson J
    Bone Marrow Transplant; 1998 Jan; 21(2):141-5. PubMed ID: 9489630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
    Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
    Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
    Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
    Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma.
    Alici E; Björkstrand B; Treschow A; Aints A; Smith CI; Gahrton G; Dilber MS
    Cancer Gene Ther; 2007 Mar; 14(3):227-32. PubMed ID: 17082794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study.
    Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F
    Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells.
    Johnson RJ; Owen RG; Smith GM; Child JA; Galvin M; Newton LJ; Rawstron A; Major K; Woodhead V; Robinson F; Jack A; Morgan GJ
    Bone Marrow Transplant; 1996 May; 17(5):723-7. PubMed ID: 8733688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma.
    Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ
    Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
    Schiller G; Vescio R; Freytes C; Spitzer G; Sahebi F; Lee M; Wu CH; Cao J; Lee JC; Hong CH
    Blood; 1995 Jul; 86(1):390-7. PubMed ID: 7540888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.
    Dyson PG; Horvath N; Joshua D; Barrow L; Van Holst NG; Brown R; Gibson J; To LB
    Bone Marrow Transplant; 2000 Jun; 25(11):1175-84. PubMed ID: 10849530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.
    Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E
    Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective.
    Bargetzi MJ; Passweg J; Baertschi E; Schoenenberger A; Gwerder C; Tichelli A; Burger J; Mingrone W; Herrmann R; Gratwohl A; Wernli M
    Bone Marrow Transplant; 2003 Jan; 31(2):99-103. PubMed ID: 12621490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.